Skip to content

Investment Proceeds at other companies

Cytokinetics logo
CytokineticsCYTK
$257.94M-6.5%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$376.36M+175%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$126.63M-57.2%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$88M-35.8%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$175.5K
Biogen logo
BiogenBIIB
$500K

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$4.18B+61.3%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0.0×
Current ratio22.6×+1.6×

Where this comes from

Reported directly by Edgewise Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities.

The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edgewise Therapeutics, Inc.'s investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edgewise Therapeutics, Inc.'s investment proceeds?
Edgewise Therapeutics, Inc. (EWTX) reported investment proceeds of $108.88M in Q1 2026.
How has Edgewise Therapeutics, Inc.'s investment proceeds changed year-over-year?
Edgewise Therapeutics, Inc.'s investment proceeds decreased by 28.0% year-over-year, from $151.12M to $108.88M.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.